Clinical Trial

MOST VIEWED

Four retina experts at a Bayer-sponsored aflibercept 8 mg symposium at EURETINA 2026 in Vienna
Posterior Segment

Dry First, Extend Later

Four retina experts on aflibercept 8 mg, from trial data to tough cases Cards on the table, votes in the room and one eye that got away. A competitive Euretina 2026 session tested what really drives aflibercept 8 mg decisions.  Five o’clock on a Friday. The last OCT is loading, the macula looks dry, and...
Marked Vision 1280 x 720 1
COOKIE | Innovation

Masked Vision

What VR can and can’t do for amblyopia Every October, kids beg for an eye patch. The rest of the year, they rip it off. Dichoptic VR promises a friendlier deal, but the trials tell a messier story, and the headset’s best trick may not be treatment at all. For a long time, the workhorse...
Retina specialist reviewing OCT imaging while planning personalized treatment for a patient
PIE | Enlightenment

The Road to 2035

What retina experts expect over the next decade The future of retina, according to the people who’ll build it: durability over dosing, phenotypes over diagnosis codes, and a capacity problem nobody’s quite solved yet.  When you’re predicting the future, especially the future of eye care, a crystal ball can be murky and easily misinterpreted. A...
Close_but_no_Eylea thumbnail
Retina

EyePoint’s Duravyu Misses Noninferiority in Second Wet AMD Phase III Trial Despite Fewer Injections

Duravyu keeps winning on durability and losing on letters. So what’s EyePoint’s next move?  EyePoint Pharmaceuticals (Massachusetts, United States) has shown for a second time that Duravyu (vorolanib intravitreal insert) can lighten the injection load in wet age-related macular degeneration (wet AMD), just not enough to clear the vision bar. The investigational sustained-release insert missed...
RNA molecule illustration representing RNA-based therapies for inherited retinal disease
PIE | Innovation

The Age of RNA

Where genetic code goes to work RNA can suppress a message, redirect splicing or guide an editor to its target, doing far more than simply carrying information from gene to protein. Retinal medicine is now testing what each of these roles can accomplish and where each approach meets resistance. Between stored genetic code and biological...
Retina specialist reviewing a fundus photograph of a diabetic patient starting semaglutide therapy
Posterior Segment

Ozempic and the Eye

What weight-loss drugs are doing to the retina “Ozempic eye” has become shorthand for two entirely different problems: one well-understood and one still under investigation. Untangling them matters, because the wrong panic could cost patients a drug that’s doing them real good elsewhere.  Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide, dulaglutide and liraglutide, along...
Researcher examining stem cell-derived retinal pigment epithelium cells in a laboratory culture dish
PIE | Innovation

The Eye Is Leading the Mission

How stem cell science is closing in on neurodegeneration Stem cells have promised to transform neurodegeneration for decades. At ARVO 2026, a pioneer in the field made the case that the promise is finally catching up with the biology…and that the eye is out in front. The eye has spent decades being treated as medicine’s...
BRUNELLO Phase IIb/III results for remigromig in diabetic macular edema presented at AAO 2026 in New Orleans
Clinical Trials

Merck’s Remigromig Meets Primary Endpoint in Phase IIb/III DME Trial

Both doses met the trial’s goal, but PDR-related adverse events were more frequent. Merck (New Jersey, USA) reported that its investigational remigromig met the primary endpoint in a pivotal trial for diabetic macular edema (DME), but higher rates of proliferative diabetic retinopathy (PDR)-related adverse events warrant further safety evaluation.* The one-year results from the Phase...

No entries were found for this taxonomy term.